Efficacy of a BCNU-based high dose conditioning regimen (CBV1) followed by autologous hematopoietic stem cell transplantation (HSCT) in relapsed or refractory Hodgkin's disease (HD).

被引：0
|
作者：
Qazilbash, MH [1 ]
Lynch, JP [1 ]
Beall, CL [1 ]
Auber, M [1 ]
Weisenborn, R [1 ]
Bunner, P [1 ]
Hobbs, G [1 ]
Ericson, SG [1 ]
机构：
[1] W Virginia Univ, BMT Sect, Morgantown, WV 26506 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5369
引用
收藏
页码：374B / 374B
页数：1
相关论文
共 50 条
  • [31] Long term follow-up of high dose cyclophosphamide, etoposide, and cisplatin followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory Hodgkin's disease.
    DiMascio, J
    Klumpp, TR
    Sabol, PJ
    Mangan, KF
    BLOOD, 2001, 98 (11) : 682A - 682A
  • [32] Autologous stem cell transplantation for children with recurrent or refractory Hodgkin's disease (HD)
    Zintl, F
    Schiller, I
    Suttorp, M
    Berthold, F
    Kabisch, H
    Peters, C
    Klingebiel, T
    Müller-Weihrich, S
    Bender-Götze, C
    Graf, N
    Friedrich, W
    Schellong, G
    Dörffel, W
    BONE MARROW TRANSPLANTATION, 1999, 23 : S106 - S106
  • [33] High-dose therapy with autologous stem cell transplantation for recurrent or refractory Hodgkin's disease (HD) in childhood.
    Zintl, F
    Schiller, I
    Suttorp, M
    Berthold, F
    Kabisch, H
    Peters, C
    Klingebiel, T
    Müller-Weihrich, S
    Bender-Götze, C
    Graf, N
    Friedrich, W
    Schellong, G
    Dörffel, W
    BLOOD, 1998, 92 (10) : 374B - 374B
  • [34] High dose cyclophosphamide, BCNU, and VP-16 (CBV), as a conditioning regimen for allogenic stem cell transplantation for patients with non-Hodgkin lymphoma.
    Jani, C
    Rossi, HA
    Emmons, RVB
    Becker, PS
    Westervelt, P
    Levy, M
    Liu, Q
    Clark, Y
    Ballen, K
    BLOOD, 2002, 100 (11) : 458B - 458B
  • [35] Role of high-dose chemotherapy with autologous haematopoetic stem cell transplantation for relapsed or refractory Hodgkin's disease.
    Kumar, Ambuj
    Djulbegovic, Benjamin
    Soares, Heloisa P.
    BLOOD, 2006, 108 (11) : 453B - 453B
  • [36] High dose therapy followed by autologous stem cell transplantation (ASCT) for patients with primary refractory Hodgkin's disease (HD): Evaluation of prognostic factors.
    Fung, HC
    Nademananee, A
    Palmer, JM
    Molina, A
    Kashyap, A
    Spielberger, R
    Hilger, J
    O'Donnell, M
    Snyder, D
    Stein, A
    Parker, P
    Bhatia, R
    Krishnan, A
    Rodriguez, R
    Vora, N
    Niland, J
    Forman, SJ
    BLOOD, 1999, 94 (10) : 175A - 175A
  • [37] High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes
    Engelhardt, Brian G.
    Holland, Derek W.
    Brandt, Stephen J.
    Chinratanalab, Wichai
    Goodman, Stacey A.
    Greer, John P.
    Jagasia, Madan H.
    Kassim, Adetola A.
    Morgan, David S.
    Ruffner, Katherine L.
    Schuening, Friedrich G.
    Wolff, Steven
    Bitting, Rhonda
    Sulur, Paulgun
    Stein, Richard S.
    LEUKEMIA & LYMPHOMA, 2007, 48 (09) : 1728 - 1735
  • [38] High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma
    Kelta, Mouhammed
    Zekri, Jamal
    Abdelghany, Ehab
    Rehman, Jalil Ur
    Khan, Zahid Amin
    Al-Saadil, Rawan
    Dadai, Reyad
    TUMORI JOURNAL, 2018, 104 (06): : 471 - 475
  • [39] High-dose chemotherapy and autologous stem cell transplantation for relapsed Hodgkin's disease.
    Fetscher, S
    Waller, CF
    Technau, K
    Wild, Y
    Lange, W
    BONE MARROW TRANSPLANTATION, 1999, 23 : S104 - S104
  • [40] Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease
    Anselmo, AP
    Cavalieri, E
    Meloni, G
    Alimena, G
    Cantonetti, M
    Enrici, RM
    Tosti, ME
    Osti, MF
    Gianfelici, V
    Mandelli, F
    HAEMATOLOGICA, 2002, 87 (05) : 507 - 511
12345